VKTX
$32.33-1.59 (-4.69%)
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype s...
Recent News
LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2D
Eli Lilly reports strong Phase III results for retatrutide in type 2 diabetes, with significant A1C reduction and up to 16.8% weight loss in the latest study.
Eli Lilly Confirms 'Superior Weight Loss' Of Its Next-Generation Obesity Drug
Eli Lilly reported study results Thursday that confirmed the "superior weight loss profile" of its next-gen obesity drug, retatrutide.
Why Is Halozyme Therapeutics (HALO) Down 13.1% Since Last Earnings Report?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?
LLY stock falls 6% after an HSBC downgrade flagged persisting U.S. pricing pressure, rising market competition and compounded tirzepatide risks, despite strong GLP-1 demand.
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics
Each of these companies could benefit from this high-growth market over time.